Ovarian cancer vaccine shows promise in early trial
NCT ID NCT04739527
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested a vaccine called DCP-001 in 17 women with a serious type of ovarian cancer who had already completed standard treatment. The goal was to see if the vaccine is safe and can boost the immune system to recognize and fight cancer cells. Researchers measured immune responses and monitored for side effects and cancer recurrence.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH GRADE SEROUS OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
UMCG
Groningen, Provincie Groningen, 9713GZ, Netherlands
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Can a new PET tracer light up hidden cancers?
- A Two-for-One surgery: could tube removal during Weight-Loss surgery slash ovarian cancer risk?
- Can AI spot ovarian cancer on CT scans before It's too late?
- Can Lab-Grown tumors unlock the secrets of ovarian cancer resistance?
- Can a smart drug home in on Hard-to-Treat cancers?